The company's File Number is listed as 001122974. Source: Aerpio Pharmaceuticals, Inc. --Aerpio Pharmaceuticals, Inc., ... clinical team and the trial investigators who have established a close collaboration in this important program,” said Joseph Gardner, President and … as Chief Medical Officer, Aerpio Therapeutics Announces Positive Results of a Phase 2a Study of AKB-9778 in Diabetic Macular Edema: The TIME-2 Trial, Aerpio Therapeutics to Present at the 14th Annual Needham Healthcare Conference, Aerpio Therapeutics Announces Publication of Positive Results of Phase 1b/2a Clinical Trial of Novel Tie2 Activator, AKB-9778, for the Treatment of Patients with Diabetic Macular Edema (DME) - TIME-1 Study, Aerpio Therapeutics Completes Enrollment of Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Patients with Diabetic Macular Edema, Aerpio Therapeutics Announces Publication of Preclinical Data on AKB-9778 for Common Eye Diseases, Aerpio Therapeutics Presents Full Results from Phase 1b/2a Study of AKB-9778, Aerpio Therapeutics Closes $22M Financing, Aerpio Therapeutics to Present at Needham Healthcare Conference, Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema, Aerpio Therapeutics Announces Successful Completion of Phase 1b/2a Trial in Diabetic Macular Edema and $9 Million Series A Extension, Aerpio Therapeutics Announces Publication of Data on Tie2 Activator, AKB-9778, Supporting Future Clinical Development in Cancer, Aerpio Therapeutics is proud to be an event sponsor for the upcoming 2012 annual NAVBO meeting, Aerpio Therapeutics Initiates Phase 1b/2a Trial of AKB-9778 in Diabetic Macular Edema, Aerpio Therapeutics Completes $27 Million Series A Financing, Aerpio Therapeutics Hosts Scientific Symposium on Tie2 Pathway, Aerpio Appoints Dr. Adrienne Graves to Board of Directors, Aerpio Announces Positive Phase 1 Data on First-in-class Tie2 Activator, AKB-9778, in Development for Diabetic Macular Edema, New Company, Aerpio Therapeutics, Created to Advance Novel Tie-2 Activators and HIF-1α Stabilizers for Multiple Diseases, COVID-19 and Acute Respiratory Disease Syndrome (ARDS). GB004 is being developed by AKB-4924’s exclusive licensor, Gossamer Bio, Inc. (Nasdaq: GOSS), in return for upfront payments totaling $35 million, future potential development, regulatory, and sales milestones of up to $90 million, and royalties on worldwide net sales. This information is according to proxy … Or Investors: Irina Koffler LifeSci Advisors ikoffler@lifesciadvisors.com. Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib (AKB-9778) Diabetic Nephropathy, Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial, Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial, Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial, Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update, Aerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19, Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10, Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19, Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial, Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients, Aerpio Reports Second Quarter 2020 Financial Results and Provides Business Update, Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12, Aerpio Pharmaceuticals, Inc. CEO: Joseph Gardner Headquarters: Cincinnati, Ohio URL: www.aerpio.com March 2017 APO Financing: $40,500,000 Trading Venue: NASDAQ CM (ARPO) Aerpio Therapeutics: Is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. 15, 2018-- Aerpio Pharmaceuticals , Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in- ... TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call and Webcast Today, March 13 th at 8:30 a.m. ... CINCINNATI --(BUSINESS WIRE)--Mar. Our lead product candidate, razuprotafib (AKB-9778), is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open angle glaucoma. Joseph Gardner is President/CEO/Founder at Aerpio Pharmaceuticals Inc. See Joseph Gardner's compensation, career history, education, & memberships. A Phase 2 trial in patients with open angle glaucoma/ocular hypertension is ongoing with top line data anticipated in Q4 2020. administered razuprotafib and ARP- 1536, a humanized Tie2-activating monoclonal antibody, in the treatment of diabetic vascular complications including nephropathy. Joseph Gardner . Goodwin Procter LLP . Aerpio Pharmaceuticals, Inc. Joseph Gardner President & Founder jgardner@aerpio.com. Aerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer and to the Board of Directors and the Transition of Joseph H. Gardner… Aerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer and to the Board of Directors and the Transition of Joseph H. Gardner… A Phase 2 trial in patients with open angle glaucoma/ocular hypertension is ongoing with top line data anticipated in Q4 2020. President . Aerpio Therapeutics, Inc. is a Massachusetts Foreign Corporation filed on December 12, 2013. Joseph Gardner, PhD, Aerpio’s President and Founder, commented “We are very pleased to have razuprotafib selected for inclusion in the I-SPY clinical trial. S . Aerpio Pharmaceuticals, Inc. 9987 Carver Road, Suite 420 . Joe Gardner. document.write(new Date().getFullYear()); It is illegal for insiders to make trades in their companies based on specific, non-public information. diabetic macular edema (DME) and wet age-related macular degeneration (wetAMD). Or. Aerpio Pharmaceuticals, Inc. 9987 Carver Road, Suite 420 . James Xu, Esq. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class orally bioavailable, gut targeted small molecule hypoxia inducible factor (HIF) prolyl hydroxylase inhibitor. It will allow us to evaluate the drug in severely ill COVID-19 patients and quickly assess both preliminary safety and efficacy and guide future development plans. 5, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ... TIME-2b Study Did Not Meet the Primary Endpoint of 2-Step Reduction in DRSS Score Conference Call and Webcast Today, March 18th at 8:30 a.m. EDT CINCI ... Top-Line Results from the TIME-2b Clinical Trial Evaluating the Effect of AKB-9778 in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) Expe ... CINCINNATI --(BUSINESS WIRE)--Feb. 26, 2019-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds ... CINCINNATI --(BUSINESS WIRE)--Jan. 17, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ... CINCINNATI --(BUSINESS WIRE)--Nov. 8, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds ... TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy On Track Conference Call and Webcast Today, November 7 th at 8:30 a.m. EST CI ... CINCINNATI --(BUSINESS WIRE)--Oct. 31, 2018-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds ... CINCINNATI --(BUSINESS WIRE)--Oct. 25, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-cl ... CINCINNATI --(BUSINESS WIRE)--Sep. 24, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-cl ... CINCINNATI --(BUSINESS WIRE)--Aug. 30, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-cl ... TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track; Data in Q2 2019 Partnership for AKB-4924 with Gossamer Bio ... CINCINNATI --(BUSINESS WIRE)--Aug. 7, 2018-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on advancing first-in-cla ... CINCINNATI --(BUSINESS WIRE)--Jun. The trial in moderate-to-severe patients is Aerpio’s second clinical trial in COVID-19 patients and is funded in part by the U . The Registered Agent on file for this company is C T Corporation System and is located at 155 Federal St., Suite 700, Boston, MA 02110. Aerpio Pharmaceuticals is a biopharmaceutical company focused on leveraging Tie2 activation for ocular disease and vascular stabilization. Patients received standard-of-care latanoprost ophthalmic solution 0.005% once-daily; and either 40 mg per … 9987 Carver Road The Company is also evaluating development options for. 25, 201 ... CINCINNATI --(BUSINESS WIRE)--Apr. Joe Gardner ... 516 others named Joseph Gardner are on LinkedIn See others named Joseph Gardner JOSEPH GARDNER (OTHER OFFICER) AERPIO THERAPEUTICS, INC. MASSACHUSETTS FOREIGN CORPORATION: WRITE REVIEW: Address: 9987 Carver Rd., Suite 420 Cincinnati, OH 45242: Registered Agent: C T Corporation System: Filing Date: December 12, 2013: File Number: 001122974: View People Named Joseph Gardner in Ohio Investors & Media: Aerpio Pharmaceuticals, Inc. Joseph Gardner President & Founder jgardner@aerpio.com. This is "Big Biz Show Interview with Dr. Joseph Gardner" by Aerpio on Vimeo, the home for high quality videos and the people who love them. James Xu, Esq. Aerpio Pharmaceuticals, Inc. Joseph Gardner President & Founder jgardner@aerpio.com. The vascular stabilizing effects of subcutaneously administered razuprotafib are being investigated in two Phase 2 trials in patients with COIVD-19 (I-SPY-COVID-19 and RESCUE) which will read out in 2021. This bispecific antibody has the potential to be an improved treatment for DME and wet age-related macular degeneration via intravitreal injection and cancer via systemic administration. Gina Marek VP Finance gmarek@aerpio.com. ARP-1536 is also in preclinical development for intravitreal administration as an adjunct to anti-VEGF therapy in patients with sight threatening retinopathies i.e. Joseph Gardner, PhD, Aerpio’s President and Founder, commented “We are very pleased to have razuprotafib selected for inclusion in the I-SPY clinical trial. Cincinnati, OH 45242 (Name and Address of Agent for Service) (513) 985-1920 (Telephone Number, Including Area Code, of Agent For Service) Copies to: Kingsley L. Taft, Esq. Dr. Joseph H. Gardner is the Founder, Pres, Principal Exec. Aerpio. Aerpio Pharmaceuticals, Inc. Joseph Gardner President & Founder jgardner@aerpio.com. Strengthened Senior Leadership Team with the Appointment of Stephen Hoffman , M.D., Ph.D., as Chief Executive Officer Effective December 1, 2017 TIME- ... CINCINNATI --(BUSINESS WIRE)--Oct. 10, 2017-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-cl ... Commenced Trading on the OTCQB ® Market Continue to Dose Patients in the TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy CIN ... © Joseph Gardner, PhD, Aerpio's President and Founder, commented "We are very pleased to have razuprotafib selected for inclusion in the I-SPY clinical trial. Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) Q3 2020 Earnings Conference Call November 10, 2020 8:30 AM ET Company Participants.